We are one of the leading generic pharmaceutical companies in Central Eastern Europe, and our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with its headquarters in France.

In the 2022/2023 financial year Egis Group generated net sales of EUR 631.7 million.

Our active ingredients and finished products – from tablets and injections, to galenic (i.e. liquid and semi-solid) formulations – are available in 100 countries. Besides Hungary, the network of  our subsidiaries and representative offices covers  17 countries,  in other countries our products are available through our partners.  

Last financial year our portfolio consisted of 653 products that belonged to 177 product lines and contained 158 active ingredients.

Our main focus lies on treating diseases of the cardiovascular and central nervous systems; however, we also provide modern treatment solutions in the fields of diabetology, dermatology and wound care. In 2013, we launched our first biosimilar monoclonal antibody product. This was also the first biosimilar monoclonal antibody (mAb) in the European Union. Since then we launched three additional biosimilar drugs.

As one of the companies in the Central Eastern European region firmly committed to innovation, we devoted EUR 48 million to R&D. Our research and development activities focus on high-quality, value-added branded generic products.

In the last twenty years we have invested EUR 834 million in improvements — such as modernizing the complete process of our finished product manufacturing, as well as establishing state-of-the-art R&D centers in Hungary. Development of highly potent (meaning having significant biological effect in very small doses) drug substances and finished products has also become possible at our site in Budapest, where the comprehensive modernization of the traditional technology of active ingredient manufacturing has also been completed. Some large-scale development activities  have been carried out at our site in Körmend: a new galenic plant was inaugurated in September 2019, while  two technology-intensive developments were launched in autumn 2021: the first phase of the major extension of the packaging plant was completed and capacity to manufacture  special medicines (typically oncology products) was established.